Lured By Its Discovery Platform And Pipeline, Amgen Bids For Nuevolution

22 May 2019

• By Sten Stovall

Amgen offered to buy its Scandinavian discovery partner for $166.8m to gain access to Nuevolution’s DNA-encoded drug discovery platform and nascent pipeline.

Fish — Amgen’s $166.8m Offer Backed By Nuevolution Board And Key Shareholders • Source: Shutterstock

Lured By Its Discovery Platform And Pipeline, Amgen Bids For Nuevolution

More from Business

More from Scrip